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Impulse control disorders (ICDs) are characterized by urges and behaviors that are excessive 
and/or harmful to oneself or others and cause significant impairment in social and occupational 
functioning, as well as legal and financial difficulties. ICDs are relatively common psychiatric 
conditions, yet are poorly understood by the general public, clinicians, and individuals struggling 
with the disorder. Although ICD treatment research is limited, studies have shown ICDs may 
respond well to pharmacological treatment. This article presents a brief overview about the clinical 
characteristics of ICDs and pharmacological treatment options for individuals with ICDs.
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Core CharaCteristiCs of impulse Control disorders
The degree to which ICDs overlap in terms of clinical, genetic, 
phenomenological, and biological characteristics is not completely 
understood. ICDs, however, have the following features in com-
mon: (1) repetitive or compulsive engagement in a behavior despite 
adverse consequences; (2) diminished control over the problematic 
behavior; (3) an appetitive urge or craving state prior to engage-
ment in the problematic behavior; and (4) a hedonic quality during 
the performance of the problematic behavior (Grant and Potenza, 
2004). These features have led to a description of ICDs as “behav-
ioral addictions” (Holden, 2010).
More recently, using neurobiological and treatment research, 
DSM-V has proposed reclassifying PG as an addictive disorder 
(due to clinical and biological similarities to substance use disor-
ders; Potenza, 2006), moving TTM into a category of obsessive– 
compulsive spectrum disorders (due to the rituals associated with 
TTM; Stein et al., 2010), and not including CSB, CB, or PSP due 
to lack of compelling biological evidence (American Psychiatric 
Association, 2010). Inclusion of PG among addictive disorders 
may advance treatment as pharmacotherapies studied in sub-
stance use disorders may be transferred into treatment research 
for PG. Inclusion of PG among other addictions may also give 
rise to research funding mechanisms currently unavailable to PG. 
However, not including other ICDs among addictions may continue 
to hamper treatment advances both due to a lack of awareness and 
funding. Discussion of where the various ICDs belong in DSM-V 
will likely be an ongoing debate.
pathologiCal gambling
Approximately 0.4–1.6% of individuals in the United States meet 
criteria for PG (Gambling Impact and Behavior Study, 1999; 
Petry et al., 2005) characterized by persistent and recurrent mala-
daptive patterns of gambling behaviors (American Psychiatric 
introduCtion
The DSM-IV formally recognizes pathological gambling (PG), 
kleptomania (KM), trichotillomania (TTM), intermittent explo-
sive disorder (IED), and pyromania as impulse control disorders 
(ICDs). Diagnostic criteria have been proposed for pathological 
skin picking (PSP), compulsive sexual behavior (CSB), and com-
pulsive buying (CB), which are currently classified under ICDs not 
otherwise specified (NOS). The core characteristic of ICDs is diffi-
culty resisting urges to engage in behaviors that are excessive and/
or ultimately harmful to oneself or others (American Psychiatric 
Association, 2000). ICDs are relatively common among adoles-
cents and adults, carry significant morbidity and mortality, and 
can often be effectively treated with behavioral and pharmaco-
logical therapies. A study of 791 college students found that 82 
(10.4%) met criteria for at least one lifetime ICD, demonstrating 
the common nature of these disorders in the general population 
(Odlaug and Grant, 2010). The intent of this review is to provide 
an updated clinical picture of the previously mentioned ICDs 
and present evidence of potential pharmacological treatments 
for these disorders (see Table 1).
methods
Clinical and pharmacological treatment information was found 
using the electronic databases, PubMed and PsychINFO, using the 
search terms “impulse control disorders,” “pathological gambling,” 
“gambling addiction,” “kleptomania,” “trichotillomania,” “hair 
pulling,” “intermittent explosive disorder,” “pyromania,” “patho-
logical skin picking,” “compulsive sexual behavior,” “sexual addic-
tion,” “compulsive buying,” “compulsive shopping,” and “shopping 
addiction.” Presented pharmacological treatment data was based 
on randomized, double-blind, controlled clinical trials published 
in academic journals. Due to examining multiple disorders, we did 
not perform a formal meta-analysis.
Edited by:
Dan J. Stein, University of Cape Town, 
South Africa
Reviewed by:
Dan J. Stein, University of Cape Town, 
South Africa
Robert David Rogers, Oxford 
University, UK
*Correspondence:
Jon E. Grant, Department of 
Psychiatry, University of Minnesota 
Medical Center, 2450 Riverside 
Avenue, Minneapolis, MN 55454, USA. 
e-mail: grant045@umn.edu
Frontiers in Psychiatry | Impulsivity, Compulsivity and Behavioral Dyscontrol  February 2011 | Volume 2 | Article 1 | 2
Schreiber et al. Impulse control disorders: updated review
Table 1 | Double-blind placebo-controlled pharmacological treatment studies of impulse control disorders.
Disorder (type of study) Treatment Outcome
AnTiDePressAnTs 
Pathological gambling (DB); 
(Hollander et al., 2000) 
Fluvoxamine (Luvox) Fluvoxamine superior to placebo
Pathological gambling (DB); (Blanco 
et al., 2002)
Fluvoxamine (Luvox) Fluvoxamine not statistically significant from placebo except in young males
Pathological gambling (DB); (Kim 
et al., 2002) 
Paroxetine (Paxil) Paroxetine group significantly improved compared to placebo 
Pathological gambling (DB); (Grant 
et al., 2003)
Paroxetine (Paxil) Paroxetine and placebo groups with comparable improvement 
Pathological gambling (DB); (Grant 
and Potenza, 2006)
Escitalopram (Lexapro) Significant improvement for escitalopram subjects while placebo group had a 
relapse of gambling symptoms
Pathological gambling (DB); 
(Sáaiz-Ruiz et al., 2005)
Sertraline (Zoloft) Sertraline did not significantly differ from placebo 
Pathological gambling (DB); (Black 
et al., 2007)
Bupropion (Wellbutrin) Bupropion did not significantly differ from placebo.
Trichotillomania (DB); (Swedo et al., 
1989)
Clomipramine (Anafranil) 
Desipramine (Norpramin)
Significant improvement with clomipramine compared to desipramine
Trichotillomania (DB); (Ninan et al., 
2000b)
Clomipramine (Anafranil) 67% of the clomipramine group were rated as “very much improved” on the 
CGI compared to none assigned to placebo. 
Trichotillomania (DB); 
(O’Sullivan et al., 1999)
Fluoxetine (Prozac)   
Clomipramine (Anafranil)
Fluoxetine and clomipramine produced similar positive results
Trichotillomania (DB); (Christenson 
et al., 1991)
Fluoxetine (Prozac) Fluoxetine produced no significant improvement compared to placebo
Trichotillomania (DB); 
(Streichenwein and Thornby, 1995)
Fluoxetine (Prozac) Fluoxetine failed to show significant improvement compared to placebo
Trichotillomania (DB); (Van Minnen 
et al., 2003)
Fluoxetine (Prozac) Fluoxetine did not demonstrate statistical superiority compared to waitlist or 
CBT 
Kleptomania (OL and DB); (Koran 
et al., 2007a)
Escitalopram Escitalopram did not significantly differ from placebo.
Intermittent explosive disorder 
(DB); (Coccaro et al., 2009) 
Fluoxetine (Prozac) Fluoxetine demonstrated superiority to placebo 
Pathologic skin picking (DB); 
(Simeon et al., 1997) 
Fluoxetine (Prozac) Fluoxetine produced significant improvement compared to placebo
Pathologic skin picking (OL and 
DB); (Bloch et al., 2001)
Fluoxetine (Prozac) 53.3% were rated as responders based on the YBOCS-–PSP in the OL. In the 
DB, only fluoxetine maintained improvement.
Pathological skin picking (DB); 
(Arbabi et al., 2008)
Citalopram (Celexa) Citalopram was not statistically superior to placebo on a visual analogue scale.
Compulsive buying (DB); (Ninan 
et al., 2000a)
Fluvoxamine (Luvox) Fluvoxamine and placebo groups with comparable improvement 
Compulsive buying (DB); (Black 
et al., 2000) 
Fluvoxamine (Luvox) Fluvoxamine and placebo groups with comparable improvement 
Compulsive buying (OL and DB); 
(Koran et al., 2003)
Citalopram (Celexa) 63% were rated as responders in the OL. In the DB, 63% of the placebo group 
relapsed compared to none of those on citalopram.
Compulsive buying (OL and DB); 
(Koran et al., 2007b)
Escitalopram (Lexapro) 73% of OL sample were rated as responders. 67% and 63% from the placebo 
and active medication group, respectively, relapsed during DB phase. 
Compulsive sexual behavior (DB); 
(Wainberg et al., 2006) 
Citalopram (Celexa) Citalopram significantly reduced desire for sex, masturbation frequency, and 
weekly hours of pornography use compared to placebo. Sexual risk decreased 
in both groups, but no significant difference was found between groups. 
(Continued)
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MOOD sTAbilizers/AnTi-ePilePTics
Pathological gambling (DB); 
(Hollander et al., 2005)
Lithium carbonate SR (Lithobid 
SR)
Lithium produced significant improvement compared to placebo
Intermittent explosive disorder 
(DB); (Hollander et al., 2003)
Divalproex sodium (Depakote) Significant changes seen in IED subjects who had a Cluster B personality 
disorder
Intermittent explosive disorder 
(DB); (Mattes, 2008)
Levetiracetam (Keppra) Levetiracetam was not superior to placebo 
Pathological skin picking (DB); 
(Grant et al., 2010) 
Lamotrigine (Lamictal) Lamotrigine did not significantly differ from placebo. Lamotrigine responders 
had impaired cognitive flexibility and delayed reach times at baseline compared 
to lamotrigine non-responders. 
OPiOiD AnTAgOnisTs
Pathological gambling (DB); (Kim 
et al., 2001)
Naltrexone (ReVia) Naltrexone group significantly improved compared to placebo
Pathological gambling (DB); (Grant 
et al., 2008).
Naltrexone (ReVia) Naltrexone group significantly improved compared to placebo
Pathological gambling (DB); 
(Toneatto et al., 2009)
Naltrexone (ReVia) Naltrexone group did not significantly differ from placebo 
Pathological gambling (DB); (Grant 
et al., 2006)
Nalmefene (Revex) Nalmafene resulted in significant improvement compared to placebo
Pathological gambling (DB); (Grant 
et al., 2010)
Nalmefene (Revex) Nalmafene did not result in significant improvement compared to placebo in an 
intent-to-treat analysis; 40 mg resulted in significant improvement when only 
those who reached target dose were analyzed
Trichotillomania (DB); (O’Sullivan 
et al., 1999)
Naltrexone (ReVia) Naltrexone significantly decreased TTM symptoms compared to placebo.
Kleptomania (DB); (Grant et al., 
2009a) 
Naltrexone (ReVia) Naltrexone was statistically superior to placebo in reducing stealing behavior
ATyPicAl neurOlePTics
Pathological gambling (DB); (Fong 
et al., 2008)
Olanzapine (Zyprexa) Olanzapine did not significantly differ from placebo 
Pathological gambling (DB); 
(McElroy et al., 2008)
Olanzapine (Zyprexa) Olanzapine did not significantly differ from placebo 
Trichotillomania (DB); (Van 
Ameringen et al., 2010)
Olanzapine (Zyprexa) Olanzapine resulted in significant improvement compared to placebo
gluTAMATergic AgenTs
Pathological gambling (OL and DB); 
(Grant et al., 2007a)
N-acetyl cysteine (NAC) 59.3% of subjects were rated as responders in the OL. In the DB, 83.3% on 
NAC still met responder criteria at study endpoint compared to 28.6% on 
placebo. 
Trichotillomania (DB); (Grant et al., 
2009b)
N-acetyl cysteine (NAC) NAC was statistically superior to placebo in reducing TTM symptoms.
DB, double-blind study; OL, open-label study.
Table 1 | continued
Disorder (type  of study) Treatment Outcome
Association, 2000). Individuals frequently start gambling in ado-
lescence or young adulthood and often gamble for years before 
the behavior becomes problematic. The mean age of PG onset is 
approximately 30 years old (Grant and Kim, 2001). Even though 
most individuals with PG are men (who typically start gambling 
at a younger age than women) approximately 28% of pathologi-
cal gamblers in the United States are women, and studies have 
shown that women tend to progress from recreational gambling 
to PG more quickly than men (Gambling Impact and Behavior 
Study, 1999; Grant and Kim, 2001; Petry et al., 2005; Sáiz-Ruiz 
et al., 2005). Impaired functioning, decreased quality of life, and 
financial, marital, and legal problems are associated with PG (Grant 
and Kim, 2001). Three proposed subtypes of PG include the impul-
sive (high risk-taking behavior and lack of planning ahead), the 
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and eyebrows (56.4%; Woods et al., 2006). TTM is associated with 
low self-esteem (Diefenbach et al., 2005). In a study of 1697 indi-
viduals with TTM, 34.6% with severe hair-pulling reported daily 
interference with occupational tasks and 48.7% reported avoiding 
social situations, such as dating or participating in group activities 
(Woods et al., 2006). Furthermore, most (79.1%) individuals with 
TTM reported that pulling episodes resulted in social anxiety due 
to alopecia (Woods et al., 2006). Despite significant distress, only 
65% of people with TTM have ever sought treatment (Woods et al., 
2006) and many go to great lengths to hide their pulling from family, 
friends, and treatment providers (Diefenbach et al., 2005).
Individuals with TTM may also struggle with other psychiatric 
conditions. Studies have found high rates of co-occurring anxi-
ety (8.9–32%), affective (51.8%), substance use (15–20%), and 
obsessive–compulsive (8.3–30.4%) disorders (Lochner et al., 2002; 
Miltenberger et al., 2006; Odlaug and Grant, 2008a). Family history 
assessments have found that first-degree family members of TTM 
subjects have substance use (29%), depressive (20%), and anxiety 
(10%) disorders (Cohen et al., 1995).
intermittent explosive disorder
Intermittent explosive disorder is characterized by recurrent, signif-
icant outbursts of aggression, which result in assaultive acts against 
people or property, are disproportionate to outside stressors, and 
not better explained by another psychiatric condition (American 
Psychiatric Association, 2000). It is estimated that 4–7% of people 
in the United States have IED and usually meet diagnostic crite-
ria during adolescence (ages 14–18; Coccaro et al., 2004; Kessler 
et al., 2006; Coccaro, 2010). Some clinical studies suggest that the 
majority (77–87.5%) of individuals with IED are males (Mattes, 
2008; Coccaro et al., 2009), however a community sample of 253 
individuals found only 37.5% were male (Coccaro et al., 2004). 
The first outburst typically occurs in early adolescence and people 
with IED have an average of 43 lifetime attacks resulting in $1359 
in property damage (Kessler et al., 2006). The majority (81.3%) also 
report significant psychosocial impairment due to IED symptoms 
(Coccaro et al., 2004). Individuals with IED consider their behavior 
distressing and problematic (McElroy et al., 1998), however, only 
28.8% of people suffering from IED have ever received treatment 
(Kessler et al., 2006).
Approximately 82% of individuals with IED have co-occurring 
Axis I psychiatric disorders, most commonly mood (11–93%), anxi-
ety (48–58.1%), and substance use (35.1–48%) disorders (Kessler 
et al., 2006; Grant, 2008). A recent family history study found that 
first-degree relatives of individuals with IED are more likely to 
have a psychiatric condition compared to control subjects, how-
ever specific rates of psychiatric conditions were not reported 
(Coccaro, 2010).
pyromania
Pyromania is characterized by deliberate and purposeful fire-setting 
on more than one occasion (American Psychiatric Association, 
2000). The prevalence of pyromania is not well established, but 
one study reported a rate of 1% in a college student sample (n = 791; 
Odlaug and Grant, 2010). A review of 282 arsonists’ hospital records 
(who were referred for a pre-trial psychiatric assessment) found 
that 23.6% who had committed other non-violent crimes and 
obsessive–compulsive (gambling is response to perceived psycho-
logical trauma), and the addictive (repetitively gambles a small 
amount of money) subtypes (Iancu et al., 2008).
It is not uncommon for pathological gamblers to struggle with 
another psychiatric disorder. Common lifetime comorbid Axis I 
disorders include mood (20–55.6%), substance use (35–76.3%), 
and anxiety (41.3–60.3%) disorders (Petry et al., 2005; Grant, 
2008; Kessler et al., 2008). Suicide attempts are also common in PG 
with one study observing attempts in 58 (17%) of 342 individu-
als (Petry and Kiluk, 2002). Studies have observed high rates of 
personality disorders in pathological gamblers (Blaszczynski and 
Steel, 1998; Petry et al., 2005). An epidemiological study of 43,093 
respondents found that 60.8% of individuals meeting DSM-IV 
criteria for PG also met criteria for a personality disorder (Petry 
et al., 2005). Having a family member with substance abuse or a 
gambling problem is also common within this population. One 
study found that 56.5% of pathological gamblers had at least 
one first-degree relative with alcohol abuse or dependence and 
26.9% had a first-degree relative with symptoms of problematic 
gambling (Grant and Kim, 2001).
Kleptomania
Kleptomania is characterized by the repetitive, uncontrol-
lable stealing of items not needed for personal use (American 
Psychiatric Association, 2000). Usually, stolen items are hoarded, 
given away, returned to the store, or thrown away (McElroy et al., 
1991). Although no large-scale epidemiologic studies have been 
conducted to assess the prevalence of KM in the general popula-
tion, a survey of college students (N = 791) found that 3 (0.38%) 
met DSM-IV criteria for KM (Odlaug and Grant, 2010). It has 
been estimated that between 3.8 and 24% of shoplifters struggle 
with KM (Arieff and Bowie, 1947; Schlueter et al., 1989). KM 
typically begins between ages 16 and 20 (Grant and Kim, 2002; 
Grant et al., 2009a), but has been reported in children as young 
as 4 (Phelan, 2002) and adults as old as 77 (McNeilly and Burke, 
1998). Studies have found that between 63 and 75% of those with 
KM are female (McElroy et al., 1991; Grant and Kim, 2002). The 
majority (64–87%) of people with KM have been apprehended 
at some time due to their stealing (McElroy et al., 1991; Grant 
and Kim, 2002).
Psychiatric comorbidity is common within this population. High 
rates of mood (36–100%), anxiety (34–80%), and substance use 
(22–50%) disorders have been documented in individuals with KM 
(Grant and Kim, 2002; Grant, 2008). High rates of mood (21%), 
substance use (20%), and anxiety (13%) disorders have also been 
found in the first-degree relatives of individuals with KM (McElroy 
et al., 1991; Grant and Kim, 2002).
triChotillomania
Trichotillomania occurs in approximately 0.5–3.9% in the United 
States (Christenson et al., 1991; Odlaug and Grant, 2010) and is 
characterized by repetitive hair-pulling causing noticeable hair 
loss and resulting in clinically significant distress or functional 
impairment (American Psychiatric Association, 2000). TTM usu-
ally begins in early puberty (11–13 years old) and is more common 
in females (93.2%; Cohen et al., 1995). Hair may be pulled from 
any area of the body, but common areas include the scalp (72.8%) 
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alcoholism (19.7%) or depression (18.3%), which was significantly 
greater than psychiatric diagnoses (18 of 162, 11.1%) in the first-
degree relatives of control subjects (Black et al., 1998).
Compulsive sexual behavior
Compulsive sexual behavior is not currently formally recognized 
by the DSM-IV, but proposed criteria include: (1) recurrent and 
intense sexual fantasies, urges or behaviors; (2) clinically signifi-
cant distress or impairment in functioning associated with sexual 
fantasies, urges, or behaviors; and (3) sexual fantasies, urges, or 
behaviors that are not better explained by other medical condi-
tions or physiological effect of an exogenous substance (Kafka, 
2010). CSB may include a wide range of sexual behaviors, includ-
ing paraphilic (e.g., exhibitionism, voyeurism, fetishes) and non-
paraphilic (e.g., masturbation, promiscuity, pornography), that 
have become unmanageable and are typically the result of attempts 
to reduce anxiety or increase pleasure (Coleman, 1992). One study 
of college students found that 3.7% reported symptoms consist-
ent with the proposed criteria for CSB (Coleman, 1992; Odlaug 
and Grant, 2010). The majority of treatment-seeking individuals 
with CSB are males with an onset during late adolescence (Black 
et al., 1997). The sexual urges and behaviors are often distress-
ing and uncontrollable, triggered by certain mood states (most 
commonly sadness or depression), and result in feelings of shame 
(Black et al., 1997).
Individuals with CSB usually have another comorbid disorder. 
Studies have found that individuals with CSB report symptoms 
consistent with substance use (64%), affective (14–39%), anxi-
ety (50%), and childhood conduct (44%) disorders (Kafka and 
Prentky, 1992; Black et al., 1997). In addition, childhood sexual 
abuse (28–78%) is common in individuals with CSB (Carries and 
Delmonico, 1996). No systematic family history studies have been 
completed, but an uncontrolled study of 75 individuals with CSB 
found that 40% had at least one chemically dependant parent and 
36% had one or two sexually addicted parents (Schneider and 
Schneider, 1996).
pharmaCologiCal treatment
Despite the high prevalence rates of ICDs in the general popula-
tion (Kessler et al., 2005) and in psychiatric cohorts (Grant et al., 
2005), pharmacological treatments have been relatively understud-
ied. There are no FDA-approved medications for any ICD. This 
treatment section focuses only on findings from double-blind, 
placebo-controlled trials.
antidepressants
Pathological gambling
Studies assessing the efficacy of fluvoxamine in treating PG have 
produced mixed results. A 16-week study using 15 subjects found 
that percent improvement of gambling symptoms was signifi-
cantly greater for fluvoxamine compared to placebo (Hollander 
et al., 2000). Yet, another trial in which 32 pathological gamblers 
participated in a 6-month trial failed to find fluvoxamine statisti-
cally superior to placebo. The results, however, were complicated 
by high rates of treatment discontinuation (only three subjects on 
medication completed the study) and by a high placebo response 
rate (59%; Blanco et al., 2002).
12.4% who had committed other violent crimes met DSM-II-R 
criteria for pyromania (Repo et al., 1997). Studies of psychiatric 
patients found that 5.9% met lifetime criteria for pyromania and 
2.8–3.4% met current criteria for pyromania (Lejoyeux et al., 2002; 
Grant et al., 2005; Grant and Kim, 2007). A study of 102 adolescent 
psychiatric inpatients reported that 6.9% met criteria for current 
pyromania (Grant et al., 2007b). Usually, pyromania develops dur-
ing adolescence and is more common in males (Grant and Kim, 
2007). Pyromania is associated with high rates of lifetime psychi-
atric comorbidity, such as affective (14–61.9%), anxiety (33.3%), 
substance use (33.3%), and impulse control (66.7%) disorders 
(Grant and Kim, 2007; Grant, 2008).
pathologiCal sKin piCKing
Pathological skin picking is characterized by repetitive or com-
pulsive picking of the skin resulting in tissue damage. The DSM 
does not formally recognize PSP, but the following criteria have 
been proposed: (1) preoccupation, impulses, or behaviors associ-
ated with skin excoriation; (2) which cause distress or interfere 
with daily functioning; and (3) are not better accounted for by 
another mental disorder or medical condition (Arnold et al., 2001). 
A random-sample, phone survey of 2513 US adults found that 
between 0.2 and 1.4% satisfied criteria for PSP (Keuthen et al., 
2010). A community sample study of 345 individuals found a 
prevalence rate of 5.4% (Hayes et al., 2009). The majority of peo-
ple with PSP are female (Keuthen et al., 2010). The area usually 
picked is the face, but any body part can be a focus (Odlaug and 
Grant, 2008b).
In addition to dealing with skin picking, individuals with PSP 
may also have a co-occurring psychiatric condition. Lifetime sub-
stance use (38%), affective (28.6–36.4%), and obsessive–compulsive 
(15.2–19%) disorders are common comorbid conditions (Lochner 
et al., 2002; Grant, 2008; Odlaug and Grant, 2008a). Psychiatric 
conditions are also common among first-degree relatives, however, 
no controlled family history studies have been completed (Arnold 
et al., 1998; Odlaug and Grant, 2008a,b).
Compulsive buying
Although the DSM does not have formal diagnostic criteria for CB, 
it is characterized by a preoccupation with buying, buying more 
than one can afford or unneeded, items, and shopping for longer 
durations of time than originally intended, resulting in marked 
distress or interference with social and occupational functioning 
(McElroy et al., 1994). The estimated prevalence of CB in the United 
States is 5.8% (Koran et al., 2006). CB behavior usually appears in 
late teens or early twenties (Black, 2007), however one study found 
that age of onset was 30 years old (McElroy et al., 1994). The major-
ity (80–95%) of individuals with CB are women (Black, 2007). 
Usually purchased items are usually not expensive, but are bought 
in large quantities resulting in excessive spending (Black, 2007). 
Purchased items typically go unused, are given away, or returned 
to the store (Schlosser et al., 1994).
Studies have also found high rates of comorbidity in the CB popu-
lation, primarily mood (21–100%), anxiety (41–80%), and substance 
use (21–46%) disorders (Schlosser et al., 1994; Grant, 2008). One 
controlled study found that 78 (56.9%) of 137 compulsive buyers 
had a first-degree relative with a psychiatric disorder, most commonly 
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placebo in reducing number of hair-pulling episodes per week or 
the amount of hair pulled per week in 21 subjects randomized into 
a double-blind, cross-over study for 18 weeks (Christenson et al., 
1991). A 31-week, double-blind, placebo-controlled, cross-over trail 
of fluoxetine of 16 subjects with TTM also failed to demonstrate any 
difference between fluoxetine and placebo in reducing hair-pulling 
behavior (Streichenwein and Thornby, 1995) The third study com-
paring fluoxetine treatment to behavioral therapy and a wait-list 
group, found that only 9% of the fluoxetine group achieved a clini-
cally significant change in hair-pulling behavior compared to 64 
and 20% of those in the behavioral therapy and wait-list group, 
respectively. Furthermore, the wait-list group had a significantly 
larger decrease in actual hair-pulling compared to the fluoxetine 
group (Van Minnen et al., 2003).
A meta-analysis of pharmacological and behavioral treatment of 
TTM found that clomipramine was superior to placebo, however 
overall SSRI treatment (including fluoxetine and sertraline) was 
not found to be superior to placebo (Bloch et al., 2007).
Kleptomania
Escitalopram has been evaluated in one clinical trial of KM. After 
completing 7 weeks of open-label escitalopram, 15 subjects (catego-
rized as responders to the open-label portion) were randomized to 
receive either escitalopram or placebo for 17 weeks. No significant 
differences were found between the two groups. In those receiving 
escitalopram, 43% relapsed and 50% on placebo relapsed and both 
groups reported similar decreases in KM symptoms from baseline 
to end of treatment (Koran et al., 2007a).
Intermittent explosive disorder
Fluoxetine has also been evaluated in treating IED and demon-
strated significant improvement in reducing frequency and severity 
of impulsive aggression and irritability in a sample of 100 subjects 
who were randomized into a 14-week, double-blind study. Despite a 
large decrease in impulsive aggression behavior from baseline, only 
44% of fluoxetine responders and 29% of all fluoxetine subjects 
were considered to be in full remission at the end of the study 
(Coccaro et al., 2009).
Pathologic skin picking
Two double-blind studies have been conducted using fluoxetine 
for the treatment of PSP. A 10-week trial with 21 subjects found 
that fluoxetine resulted in significant improvements in skin pick-
ing symptomology on a visual analog scale compared to placebo 
(Simeon et al., 1997). Another study randomized 8 (53.3%) of 
15 open-label fluoxetine responders (defined as a 30% or greater 
decrease in YBOCS–PSP scores) into a 6-week double-blind dis-
continuation period. The four subjects assigned to fluoxetine 
maintained their levels of improvement and demonstrated a 70% 
reduction in picking behavior while those on placebo returned to 
their baseline symptom severity level (Bloch et al., 2001).
One study examined the efficacy of citalopram in treating PSP 
and found that the 23 subjects randomized to receive 10–20 mg/
day of citalopram for 4 weeks had decreased severity of skin pick-
ing behavior (measured by a visual analog scale) compared to the 
22 subjects on placebo, however this decrease was not statistically 
significant (Arbabi et al., 2008).
Paroxetine has also been examined in PG and demonstrated 
varying results. An 8-week study demonstrated significantly greater 
reductions in gambling urges and behavior compared to placebo 
(Kim et al., 2002). In contrast, a larger 16-week trial of 76 subjects 
found that paroxetine did not demonstrate statistical significance 
over placebo on any measure. A high placebo response rate (48%) 
was observed in those assigned to placebo compared to 59% response 
rate of those randomized to paroxetine (Grant et al., 2003).
An open-label, 12-week trial of escitalopram with an 8-week, 
double-blind discontinuation period for responders, was performed 
in 13 PG subjects with co-occurring anxiety disorders. Unlike many 
clinical trials in this population, current psychiatric comorbidity 
was not exclusionary. Of the 13 subjects treated with a mean dose 
of 25.4 mg/day, 8 (62%) were considered responders [defined as 
30% or greater reduction in Yale-Brown Obsessive Compulsive 
Scale Modified for Pathological Gambling (PG-YBOCS) total score 
at endpoint compared to baseline] in terms of both PG and anxiety 
symptoms. Four of six subjects who were responders were rand-
omized into an 8-week, double-blind discontinuation study. Of the 
three assigned to escitalopram, improvement continued for the next 
8 weeks in all three cases, whereas both gambling symptoms and 
anxiety returned within 4 weeks to baseline levels for the subject 
assigned to placebo, suggesting that escitalopram may effectively 
decrease both anxiety and gambling (Grant and Potenza, 2006).
In a 6-month double-blind, placebo-controlled study using sertra-
line for 60 PG subjects, 23 of the 31 subjects randomized to sertraline 
(74%) and 21 of 29 subjects assigned to placebo (72%) were rated as 
responders [as measured by the Criteria for Control of Pathological 
Gambling Questionnaire (CCPGQ)] at endpoint. Scores between 
groups did not statistically differ (Sáiz-Ruiz et al., 2005).
In the only study to examine a non-serotonergic antidepressant, 
bupropion was tested in 39 PG subjects in a 12-week, flexible dose 
trial. The study found that there were no significant differences 
between the bupropion and the placebo groups in the improvement 
of gambling behavior and thoughts/urges, or time or money spent 
on gambling per week (Black et al., 2007).
Trichotillomania
Several controlled pharmacological trials using antidepressants 
have been conducted in TTM. One study examined clomipramine 
compared to desipramine in a 10-week, double-blind, cross-over 
(5 weeks for each agent) design (following 2 weeks of single-blind 
placebo lead-in) in 13 females. The clomipramine group experi-
enced significant decreases in the severity, frequency, and intensity 
of hair-pulling compared to desipramine (Swedo et al., 1989). A 
9-week, placebo-controlled, randomized, parallel-treatment study 
of cognitive behavioral therapy (CBT) and clomipramine with 16 
subjects, however, found that clomipramine did not result in sig-
nificantly greater response (Ninan et al., 2000b).
Pigott and colleagues (1992; as cited by O’Sullivan et al., 1999) 
compared fluoxetine with clomipramine in a double-blind, rand-
omized, 20-week cross-over design (10 weeks on each medication) 
and found that both clomipramine and fluoxetine demonstrated a 
similar positive treatment effect in terms of reducing hair-pulling 
behavior (O’Sullivan et al., 1999). Three other studies investigat-
ing fluoxetine, however, failed to demonstrate efficacy in treating 
TTM. One study found that fluoxetine was no more effective than 
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(except an escitalopram study for PG) and rarely went beyond 
3–4 months (except one fluvoxamine and one sertraline study for 
PG), the generalizability of these findings is still unclear.
mood stabilizers/anti-epileptiCs
Pathological gambling
The only placebo-controlled study of a mood stabilizer in PG exam-
ined lithium in pathological gamblers with co-occurring bipolar 
spectrum disorders. The study randomized 40 subjects in a dou-
ble-blind, placebo-controlled trial for 10 weeks. Results indicated 
that sustained-release lithium carbonate demonstrate significantly 
greater improvement than placebo in reducing gambling thoughts/
urges and behaviors and overall gambling severity. Furthermore, 
significantly more subjects on the active medication were rated as 
responders (defined by a CGI score of 1 or 2 and 35% or greater 
reducing in PG–YBOCS score) compared to those on placebo (83.3 
vs. 29.4%; Hollander et al., 2005).
Intermittent explosive disorder
Ninety-six subjects with Cluster B personality disorders, 116 with 
IED, and 34 with post-traumatic stress disorder were randomized 
to 12 weeks of divalproex sodium or placebo. Divalproex was not 
found to have a significant influence on aggression, irritability, or 
clinical improvement in the subjects with IED without a Cluster 
B personality disorder (Hollander et al., 2003).
Another study assessed levetiracetam in 40 subjects with clini-
cally significant impulsive aggression (which met Coccaro and 
colleagues’ refined criteria for IED) in a 10-week, double-blind, 
placebo-controlled, variable dose study and found levetiracetam 
was not superior to placebo on measures of aggression [assessed by 
the Overt Aggression Scale-Modified (OAS-M)], hostility [assessed 
by the Brief Psychiatric Rating Scale (BPRS) hostility scale], or 
patient-rated global improvement (Mattes, 2008).
Pathologic skin picking
The anticonvulsant, lamotrigine, has been used in one double-blind 
study to treat PSP in 35 subjects in a 12-week study. Lamotrigine 
failed to demonstrate significant improvement on any measure 
of PSP severity. Further analysis, however, showed that those who 
responded to lamotrigine had impaired cognitive flexibility and 
longer reaction times at baseline compared to lamotrigine non-
responders (Grant et al., 2010).
Summary of mood stabilizers/anti-epileptic treatments for ICDs
The data regarding mood stabilizer or anti-epileptic medications 
in the treatment of ICDs is far too limited to make any useful 
clinical conclusions. Not all medications in this category have the 
same pharmacological mechanism and these medications have been 
tested in only a few of the ICDs. The studies do however demonstrate 
that classifying subtypes of individuals with ICDs based on per-
ceived pathophysiologies (e.g., gamblers with co-occurring bipolar 
spectrum disorders or pathological pickers with specific cognitive 
deficits) may allow for more targeted and more effective pharma-
cotherapies. Some research has suggested treating the impulsive 
subtype of PG with mood stabilizers (Iancu et al., 2008). Future 
studies may want to examine which ICDs, and/or which individuals 
with specific ICDs, may respond to these medications.
Compulsive buying
Four double-blind randomized, placebo-controlled trials using 
antidepressants in CB have been published. In one study, 37 CB 
subjects were treated with fluvoxamine for 13 weeks. Both the flu-
voxamine and placebo groups significantly improved from baseline 
on measures of CB thoughts/urges and behaviors (Ninan et al., 
2000a). Similar results were found by Black et al. (2000) who found 
no difference in response rates when comparing fluvoxamine to 
placebo in 23 participants treated for 9 weeks.
In a 7-week citalopram study, researchers found a 63% response 
rate [measured by a CGI-I score of 1 or 2 and a 50% or greater score 
decrease in Yale-Brown Obsessive Compulsive Scale – Shopping 
Version (YBOCS–SV) from baseline] in 24 subjects. Those who 
responded were entered into the 9-week, double-blind treatment 
phase. Five (63%) on placebo compared to none on citalopram 
relapsed (defined as YBOCS–SV score or 17 or more and CGI-I score 
of “minimally improved” or less). Furthermore, shopping thoughts/
urges and behavior increased in the placebo group while decreasing in 
the citalopram group from week 7 to endpoint (Koran et al., 2003).
An escitalopram study for CB failed to show efficacy for the 
treatment of CB. Seventeen participants were responders (defined 
as CGI-I score of a 1 or 2 and YBOCS–SV score of <17, with a 
50% or greater decrease from baseline) in a 7-week open-label 
period and then randomized into a 9-week, double-blind, discon-
tinuation phase. Six (67%) of the placebo group and five (63%) 
of the active group relapsed (defined as ≥17 and CGI-I score of 
minimally improved or less) in the discontinuation phase (Koran 
et al., 2007b).
Compulsive sexual behavior
There is limited research concerning pharmacotherapy in treat-
ing CSB. In one 12-week, double-blind, placebo-controlled study, 
citalopram demonstrated significant reductions in the desire for 
sex, frequency of masturbation, and hours of pornography use per 
week in a sample of 28 gay and bisexual men compared to placebo. 
However, subjects in both groups, reported similar reductions in 
risky sexual behavior (Wainberg et al., 2006).
Summary of antidepressant treatment of ICDs
Although far from conclusive, the limited data from antidepressant 
trials for ICDs provide some important clinical and research direc-
tions: (1) serotonergic antidepressants may be useful for some of 
the ICDs (IED, PSP, CB, and CSB); (2) not all serotonergic medica-
tions may be equally efficacious (clomipramine resulted in some 
improvement for TTM whereas fluoxetine did not; fluvoxamine was 
not effective for CB but citalopram demonstrated some benefit); (3) 
trials need to be longer due to the high placebo response in indi-
viduals with ICDs; and (4) a specific treatment may be beneficial 
for some individuals with certain ICDs but the treatment may not 
be broadly effective for everyone with a specific ICD diagnosis. 
The trials essentially demonstrate that serotonergic antidepressants 
may have a role in the treatment of certain ICDs or certain indi-
viduals with ICDs. For example, Iancu et al. (2008) suggests trying 
an SSRI for the obsessive–compulsive subtype of PG and starting 
with bupropion for the addictive subtype. Given the high rates of 
comorbidity in ICDs and the chronic natures of these disorders, 
however, the fact that the studies rarely included any comorbidity 
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study which enrolled comorbid alcohol use disorders and one 
naltrexone study that enrolled subjects with depression and anxi-
ety). The evidence for the use of opioid antagonists in KM is also 
promising and given that an escitalopram study was negative, this 
study suggests opioid antagonists may be the direction of choice for 
future research of this disorder. The evidence for opioid antago-
nists for TTM are limited by a study with mixed results (some 
measures positives, others not). This class of medications should 
be considered the first-line treatment for PG and KM based on the 
data thus far. Future studies should examine opioid antagonists 
for a wider range of ICDs.
atypiCal neuroleptiCs
Pathological gambling
Two studies have assessed the use of olanzapine in treating PG with 
both finding that olanzapine was no more effective than placebo. 
In a study of 21 PG subjects treated for 7 weeks with olanzapine, 
results indicated that all subjects had decreased gambling urges 
and behaviors but no statistical differences were found between 
the two groups (Fong et al., 2008). Similarly, McElroy et al. (2008) 
found that olanzapine was not superior to placebo in a study of 42 
subjects in a 12-week study.
Trichotillomania
A 12-week randomized, double-blind, placebo-controlled trial of 
olanzapine, demonstrated significant improvement on measures 
of TTM severity in 25 subjects with TTM. Furthermore, 85% of 
subjects on active medication (compared to 17% in the placebo 
group) were considered to be full responders (Van Ameringen 
et al., 2010).
Summary of atypical antipsychotic treatment for ICDs
The data regarding the use of atypical antipsychotic treatment for 
PG strongly suggest that these medications provide no benefit. 
The data for TTM, however, are very persuasive although it was a 
very small study. The questions remains whether different atypi-
cal antipsychotics may produce different results in ICDs. Given 
the side effect profile of these medications, however, they should 
be used with caution and with monitoring of potential health-
related side effects.
glutamatergiC agents
Pathological gambling
N-acetyl cysteine (NAC) has been found to be effective in decreasing 
PG symptoms in an 8-week, open-label trial of NAC followed by 
6-week, double-blind discontinuation phase, Grant et al. (2007a) 
found that NAC was effective in reducing gambling thoughts/
urges and behaviors and improving level of functioning in 27 
subjects. Of those responder subjects randomized to NAC, 83.3% 
still met responder criteria, while 28.6% assigned to placebo met 
responder criteria.
Trichotillomania
Using a sample of 50 individuals with TTM, subjects randomized to 
receive NAC for 12 weeks had significantly greater reductions in TTM 
symptomology on both the MGH-HPS (self-report scale) and the 
Psychiatric Institute Trichotillomania Scale (clinician- administered 
opioid antagonists
Pathological gambling
Studies investigating naltrexone in the treatment of PG have pro-
duced generally positive results. Forty-five pathological gamblers 
randomized to 12 weeks of naltrexone or placebo found that 
naltrexone was significantly more effective at reducing PG urges 
and behavior (Kim et al., 2001). Similar results were found in an 
18-week trial of 77 PG subjects. The naltrexone group had sig-
nificantly greater decreases in gambling urges and behaviors, and 
greater overall improvements in gambling severity (Grant et al., 
2008). In contrast, Toneatto et al. (2009) found no differences 
between naltrexone and placebo in terms of gambling frequency 
or expenditures in a sample of 52 subjects with PG and co-current 
alcohol use disorder alcoholism. During the 11-week study, subjects 
also received up to seven sessions of CBT.
A 16-week study of 207 subjects treated with nalmefene found 
that those on active medication demonstrated significantly greater 
reductions in gambling symptoms compared to placebo (Grant 
et al., 2006). A second study of nalmefene in 233 PG subjects treated 
for 12 weeks with lower doses found that, using an intent-to-treat 
analysis, nalmefene was not superior to placebo on gambling 
thoughts/urges and behaviors and overall gambling behaviors. 
When the analyses were limited to those subjects who achieved 
the full assigned dose of medication, however, those assigned to 
40 mg/day reported significantly greater reduction in gambling 
urges (Grant et al., 2010).
Trichotillomania
Using a 6-week, double-blind design, 17 individuals with TTM were 
randomized to receive either naltrexone or placebo. The naltrexone 
group experienced significant decreases in TTM symptom severity 
compared to placebo. About half (three of seven) taking naltrexone 
reported a 50% decrease in hair-pulling symptoms compared to 
none on placebo. However, groups were not significantly different on 
measures of number of hair-pulling episodes, level of impairment, 
and clinician’s ratings of symptoms (O’Sullivan et al., 1999).
Kleptomania
A study of 25 KM subjects randomized into an 8-week, double-
blind, placebo-controlled study, found naltrexone significantly 
reduced urges to steal and stealing behavior compared to placebo. 
Nineteen of 25 (76%) of all subjects had at least one comorbid dis-
order, most commonly major depressive (44%) and anxiety (32%) 
disorders (Grant et al., 2009a).
Summary of opioid antagonist treatments for ICDs
The data regarding the use of opioid antagonists for PG are per-
suasive and provide the strongest evidence of any medication for 
the treatment of ICDs. There have been four positive studies and 
one negative study, although the negative study used dosing of 
naltrexone which was lower than previously reported in the suc-
cessful trials. These studies may suggest that dosing of the opioid 
antagonist may be important for successful clinical outcome. One 
study also determined that those PG subjects with a family history 
of alcohol use disorders may respond more robustly to opioid 
antagonists (Grant et al., 2008). These studies, however, generally 
did not enroll those with comorbidities (except one naltrexone 
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Although ICDs present significant public health concerns, 
researchers and clinicians have paid relatively little attention 
to these conditions. As represented in this article, significant 
advances have been made in the exploration of pharmacological 
treatments for ICDs. Further advances, however, must be made. 
Generalizability of these studies is limited as the majority of sam-
ples lack adequately powered samples, high placebo-response rates, 
and limited follow-up periods. Additional large-scale, placebo-
controlled, comparative pharmacological treatment studies need 
to be completed to find the most effective treatments for ICDs. 
Furthermore, the replication of promising treatment studies and 
additional clinical trials comparing medications and therapies are 
needed to accurately assess which treatments are effective and in 
whom. Knowledge gained from these studies will not only advance 
the treatment of ICDs, but also significantly improve the lives of 
those with ICDs and those who are directly and indirectly affected 
by their conditions.
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assigned to placebo (Grant et al., 2009b).
Summary of glutamatergic agents for ICDs
The data regarding the use of NAC for both TTM and PG are 
encouraging. Both studies enrolled subjects with co-occurring anxi-
ety and depression and therefore the results may generalize better to 
the population at large. The studies highlight that focusing on the 
glutamate system may be potentially beneficial when considering 
treatment for ICDs.
summary
Treating ICDs is difficult because individuals with ICDs often are 
conflicted with the desire to engage in the behavior and their desire 
to stop the behavior. Thus, physicians should carefully assess the 
situations that cause individuals to seek help. Clinicians also need to 
stay cognizant of comorbid disorders because ICD symptomology 
may worsen with co-occurring disorders and co-occurring disor-
ders may interfere with treatment outcomes. Most pharmacological 
trials have excluded individuals with current co-occurring primary 
Axis I disorders. With such high proportions of ICD patients endur-
ing co-occurring conditions, future clinical trials should investigate 
how specific comorbidities distinctly influence treatment results. 
These findings will advance knowledge about the efficacy of treat-
ment for these often co-occurring problems.
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